Updates
Red Mail
27°
Tel Aviv-Jaffa
Search
Main
Israel News
Mideast & World News
Tech & Digital
Real Estate
Finance
Lifestyle
Health & Science
Jewish World
Travel
More
Channels
Opinions
Magazine
Sports
Food
Weather
Podcasts
Sites & Sources
Ynet
Calcalist
yad2
ynetespanol
Вести
mynet
Contact
Contact us
Privacy Policy
Terms of Use
Accessibility Statement
main
Israel News
Mideast & World News
Tech & Digital
Real Estate
Finance
Lifestyle
Health & Science
Jewish World
Travel
27°
Weather
YnetGlobal Channels
Opinions & Analysis
Magazine
Food
Sports
Weather
Podcasts
Sites & Sources
ynet
calcalist
yad2
Español
Вести
mynet
more channels
Israel News
Mideast & World News
Tech & Digital
Finance
Lifestyle
Health & Science
Travel
Contact
Contact us
Privacy Policy
Terms of Use
Accessibility Statement
Tags
TEVA
Britain’s largest nursing union drops Teva sponsorship after pro-Palestinian pressure
The Royal College of Nursing, representing more than 500,000 nursing staff, ended its partnership with Teva UK and dropped its sponsorship of an October conference following pressure from pro-Palestinian groups
Oren Rice
|
10.03.26
Teva Ukraine warehouse hit twice in Russian attack, raising supply concerns
Teva Ukraine says a Russian attack struck its warehouse twice, with no employees injured; The pharmaceutical company is assessing the damage while working to prevent disruptions to medicine supplies for Ukrainian patients
ynet Global, News Agencies
|
09.04.26
Teva celiac drug protects gut from gluten damage after single injection in trial
TEV ‘408 met its main Phase 2a goal, cutting intestinal damage and inflammation during six weeks of daily gluten exposure, with no safety signals observed to date
Oren Rice
|
09.02.26
Moody’s upgrades Teva to investment grade, citing growth and continued debt reduction
Ratings agency raises Israeli drugmaker to Baa3 with a stable outlook, pointing to stronger earnings, improving margins, solid cash flow and expectations that debt will continue to fall over the next 12 to 18 months
ynet Global
|
08.11.26
Teva advances experimental vitiligo drug after encouraging early results
Israeli drugmaker says TEV-408, an anti-IL-15 antibody designed for quarterly dosing, improved skin pigmentation in an early-stage study and will move into Phase 2b development later this year
ynet Global
|
07.07.26
Pharma giant Teva to cut 250 jobs at Israel plant
Layoffs at Teva Tech in Ramat Hovav are part of a global restructuring of TAPI, Teva’s active pharmaceutical ingredients unit, as the company weighs a possible sale
Navit Zomer
|
06.10.26
Teva regains investment-grade rating from Fitch
Fitch points to expected growth from drugs including Austedo and Ajovy; Teva is still rated below investment grade by S&P Global Ratings, at BB+ with a stable outlook, and by Moody’s, at Ba1 with a positive outlook
ynet Global
|
05.18.26
Teva resumes acquisitions with $900 million Emalex deal after decade-long hiatus
Teva will pay $700 million upfront and up to $200 million more for Emalex, which develops a Tourette syndrome treatment granted orphan drug status; the deal comes as the company reports $4 billion in quarterly revenue and $369 million in net profit, beating forecasts
Navit Zomer
|
04.29.26
From Netanya labs to global race: Teva develops antibody targeting celiac and autoimmune diseases
Backed by up to $500 million deal, Teva advances experimental antibody for celiac and vitiligo, aiming to stop autoimmune disease at its source; researcher offers rare look inside complex path from lab to patients
Eitan Gefen
|
04.07.26
Teva shares slide as 2026 forecast disappoints despite strong 2025 earnings
Israel-based pharma giant posts $17.3 billion in 2025 revenue and 19% profit growth, but stock falls on lower-than-expected 2026 outlook, even as CEO touts pipeline potential and billion-dollar quarter from flagship drugs
Navit Zomer
|
01.28.26
Teva’s billion-dollar bet to treat celiac and vitiligo
Teva is investing up to $500 million in a new antibody it hopes can transform treatment for vitiligo and celiac disease, two autoimmune conditions with limited options and major unmet medical needs
Tzur Gueta
|
01.13.26
Teva, Royalty Pharma announce $500M deal to advance autoimmune drug
New partnership aimed at advancing Israeli pharma giant's anti-IL-15 drug for autoimmune diseases; CEO Richard Francis to detail growth strategy and pipeline progress at J.P. Morgan Healthcare Conference on Jan. 13
ynet Global
|
01.12.26
Teva launches new global innovation program, will fully fund startup pilots
Teva is opening a call for startups in Israel and abroad as part of its new Rise program, offering full funding for pilots, rapid integration and support across seven innovation domains, in a move to accelerate drug development and supply-chain efficiency
Tal Shahaf
|
11.20.25
Italian Jewish Medical Association demands action after hospital staff film anti-Israel Teva drug disposal
Dr. Daniel Radzik says letters to Health Minister and hospital were necessary to force apology after Tuscany medical staff filmed anti-Israel video; calls incident part of growing antisemitic climate across Europe; 'Medicines must not be used as tools of political or ideological dispute'
Ynetnews
|
08.21.25
Outrage in Italy after medical staff seen discarding Israeli-made Teva medications
Protest targeting Israeli pharmaceutical giant Teva comes amid rising anti-Israel sentiment in Italy; pair later apologize, calling it 'a symbolic gesture for peace' and claiming no medicine actually discarded
Daniel Bettini
|
08.20.25
More Articles
Hot Tags
Today
This Week
This Month
9/11
Abbas Kamel
accident
agriculture
AI
Aliyah
Amine Ayoub
Ancient Egypt
Antiques
Antisemitism
Hot Tags
Today
This Week
This Month
9/11
Abbas Kamel
accident
agriculture
AI
Aliyah
Amine Ayoub
Ancient Egypt
Antiques
Antisemitism
Related Tags
Russia
Ukraine
United Kingdom
Russia-Ukraine war
Boycott
Stock Market
medicine
Tel Aviv Stock Exchange
Layoffs
stocks
""